Real-word evidence on healthcare resource use and associated costs in on-demand users of replacement therapies in von Willebrand disease in France: the FORvWARD study.
seems to be a cost-saving RT compared with other RT. Future studies including clinical data should provide further evidence.
Authors
- Claire Marant Micallef (ORCID: https://orcid.org/0000-0002-5635-8605)
- B. Polack
- Marc Trossaërt (ORCID: https://orcid.org/0000-0003-4072-839X)
- Franck Favre-Besse
- M. Belhassen
- Virginie Nerich (ORCID: https://orcid.org/0000-0002-0351-6040)
- Mélanie Nee (ORCID: https://orcid.org/0000-0001-7016-501X)
- Catherine Chatelanaz
- J. Beoletto
- Cinira Lefèvre
- Christine Biron-Andréani
- Nadège Bornier
- Gérard de Pouvourville
- Mélanie Née
Institutions
- École Supérieure des Sciences Économiques et Commerciales (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Techniques of Informatics and Microelectronics for Integrated Systems Architecture (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Centre d'Investigation Clinique de Nantes (FR)
- Translational Innovation in Medicine and Complexity (FR)
- CY Cergy Paris Université (FR)
- Takeda (France) (FR)
- École de management de Lyon (FR)
- Université Grenoble Alpes (FR)
- Université de Franche-Comté (FR)
Publication Details
- Journal
- PubMed
- Published
- 2026-04-01
- DOI
- https://doi.org/10.57264/cer-2025-0128
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00